EUVIMEDEUVIMED entdecken
Kommentar

In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events

Reem Al-Jabri, Waqqas Afif

Annals of Internal Medicine · 2023

DOI: 10.7326/j23-0048 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Reem Al-Jabri und 1 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Health Center, Montreal, Quebec, Canada (R.A., W.A.). Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SOURCE CITATION: Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159-1171. 36871574.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansAcetatesDouble-Blind MethodIndolesInduction ChemotherapyRemission InductionRandomized Controlled Trials as Topic

Substanzen

AcetatesetrasimodIndoles

Autor:innen und Institutionen

  • McGill University Health Center, Montreal, Quebec, Canada (R.A., W.A.).

Zitieren

APA

Al-Jabri, R., & Afif, W. (2023). In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events. Annals of Internal Medicine. https://doi.org/10.7326/j23-0048

Vancouver

Al-Jabri R, Afif W. In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events. Annals of Internal Medicine. 2023. doi:10.7326/j23-0048

BibTeX
@article{AlJabri2023,
  author = {Al-Jabri, Reem and Afif, Waqqas},
  title = {In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/j23-0048}
}
Kostenlos starten →